Zhang Jinguo, Wang Fanchen, Liu Fangran, Xu Guoxiong
Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai, China.
Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, 1508 Longhang Road, Shanghai, 201508, P.R. China.
Ther Adv Med Oncol. 2020 May 8;12:1758835920917558. doi: 10.1177/1758835920917558. eCollection 2020.
Aberrant activities of signal transducer and activator of transcription 1 (STAT1) have been implicated in cancer development. However, the prognostic value of STAT1 remains unclear. This report identified the role of STAT1 in prognosis in patients with solid cancer through open literature and The Cancer Genome Atlas (TCGA) database.
Published articles were obtained from PubMed, Web of Science, and Embase databases according to a search strategy up to October 2019. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted to assess the prognostic factors of patients. TCGA datasets were used to explore the prognostic value of STAT1 in various cancers.
A total of 15 studies incorporating 2839 patients with solid cancers were included. Pooled data showed that overexpressed STAT1 favored long overall survival (OS) (HR = 0.604, 95% CI = 0.431-0.846, = 0.003) and disease-specific survival (DSS) (HR = 0.650, 95% CI = 0.512-0.825, = 0.000). In subgroup analyses, highly expressed STAT1 was correlated with long OS of patients with high-grade serous ovarian cancer and oral squamous cell carcinoma. Data extracted from TCGA datasets unveiled that STAT1 expression was significantly higher in 12 cancers (e.g. bladder and breast) than their adjacent normal tissues. Again, highly expressed STAT1 favored long OS of patients with ovarian cancer as well as rectum adenocarcinoma, sarcoma, and skin cutaneous melanoma. However, in renal carcinoma, brain lower grade glioma, lung adenocarcinoma, and pancreatic cancer, highly expressed STAT1 was correlated with poor OS of patients. Particularly in renal carcinoma, increased STAT1 expression was associated with high grade, later stage, large tumor size, and lymph node and distant metastasis.
STAT1 has been identified to have prognostic value in patients with solid cancer. Highly expressed STAT1 may predict prognosis in cancer patients based on their tumor types.
信号转导与转录激活因子1（STAT1）的异常活性与癌症发展有关。然而，STAT1的预后价值仍不清楚。本报告通过公开文献和癌症基因组图谱（TCGA）数据库确定了STAT1在实体癌患者预后中的作用。
根据检索策略，从PubMed、Web of Science和Embase数据库中获取截至2019年10月发表的文章。提取合并风险比（HR）及95%置信区间（CI）以评估患者的预后因素。使用TCGA数据集探讨STAT1在各种癌症中的预后价值。
共纳入15项研究，涉及2839例实体癌患者。汇总数据显示，STAT1过表达有利于总生存期（OS）延长（HR = 0.604，95%CI = 0.431 - 0.846，P = 0.003）和疾病特异性生存期（DSS）延长（HR = 0.650，95%CI = 0.512 - 0.825，P = 0.000）。在亚组分析中，高表达的STAT1与高级别浆液性卵巢癌和口腔鳞状细胞癌患者的长OS相关。从TCGA数据集中提取的数据显示，12种癌症（如膀胱癌和乳腺癌）中STAT1表达明显高于其相邻正常组织。同样，高表达的STAT1有利于卵巢癌、直肠腺癌、肉瘤和皮肤黑色素瘤患者的长OS。然而，在肾癌、脑低级胶质瘤、肺腺癌和胰腺癌中，高表达的STAT1与患者的不良OS相关。特别是在肾癌中，STAT1表达增加与高分级、晚期、大肿瘤大小以及淋巴结和远处转移相关。
已确定STAT1在实体癌患者中具有预后价值。高表达的STAT1可能根据肿瘤类型预测癌症患者的预后。
